Literature DB >> 14617036

The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis.

T Ahmad1, A Armuzzi, M Neville, M Bunce, K-L Ling, K I Welsh, S E Marshall, D P Jewell.   

Abstract

Linkage and association studies implicate the human leucocyte antigen (HLA) region in genetic susceptibility to ulcerative colitis (UC). However, associations with specific variants have been inconsistent, even within defined ethnic groups. A genetic basis for the disease heterogeneity of UC may account for these discrepant findings from studies in unselected populations. Here, we examine the contribution of the HLA region to the clinical phenotype of UC. We studied 321 accurately phenotyped patients recruited from a single UK centre, with a median follow-up time of 15 years. Individuals were genotyped for 340 polymorphisms constructed into 25 gene-specific allelic haplotypes between HLA-A and Tapasin. Data were analysed with respect to age of onset, disease extent and severity. Strongest association with overall susceptibility was identified with HLA-DRB1 alleles replicating previous studies (DRB1*0103, DRB1*1502 and DRB1*0401). We report a novel association with homozygosity of a tumour necrosis factor (TNF) promoter haplotype (TNF-1031T, -863C, -857C, -380G, -308G and -238G) and distal disease extent that does not extend with time (distal vs total 40.9 vs 25.7%; RR = 2.0; 95% CI 1.23-3.24). We confirm the association of DRB1*0103 with total disease and/or disease requiring colectomy and further demonstrate that DRB1*0103 is associated with shorter time to surgery. Genes in the HLA play a role in modifying disease phenotype. Further studies are required to dissect how these genes functionally interact with each other and with environmental factors to determine clinical patterns of disease

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617036     DOI: 10.1046/j.1399-0039.2003.00129.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  21 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 2.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 3.  Genetics of inflammatory bowel disease: current status and future directions.

Authors:  Thomas D Walters; Mark S Silverberg
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

Review 4.  What is the origin of ulcerative colitis? Still more questions than answers.

Authors:  Milan Lukas; Martin Bortlik; Zdenek Maratka
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

Review 5.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

6.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

7.  MICB0106 gene polymorphism is associated with ulcerative colitis in central China.

Authors:  Yi Li; Bing Xia; Min Lü; Liuqing Ge; Xiaolian Zhang
Journal:  Int J Colorectal Dis       Date:  2009-08-07       Impact factor: 2.571

Review 8.  The future of molecular approaches to inflammatory bowel disease.

Authors:  Boyko Kabakchiev; Smita Halder; Mark S Silverberg
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 9.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

10.  Infliximab in ulcerative colitis.

Authors:  Avi Levin; Oren Shibolet
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.